Eiger Corporate News

Home»Eiger Corporate News
26 05, 2020

Eiger to Present at Jefferies Virtual Healthcare Conference 2020

2020-05-26T21:20:28+00:00

Eiger to Present at Jefferies Virtual Healthcare Conference 2020 PALO ALTO, Calif. – May 26, 2020 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, [...]

Eiger to Present at Jefferies Virtual Healthcare Conference 20202020-05-26T21:20:28+00:00
7 05, 2020

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-07T20:42:20+00:00

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update PALO ALTO, Calif. May 7, 2020 — Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for first quarter 2020 and provided a business update. “We achieved key milestones [...]

Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update2020-05-07T20:42:20+00:00
30 04, 2020

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda

2020-04-30T13:57:03+00:00

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda Six International, Investigator Sponsored Studies Initiating and Enrolling PALO ALTO, Calif. April 30, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in [...]

Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda2020-04-30T13:57:03+00:00
3 04, 2020

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic

2020-04-03T11:04:09+00:00

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating   PALO ALTO, Calif. April 1, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare [...]

Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic2020-04-03T11:04:09+00:00
13 03, 2020

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

2020-03-13T15:27:43+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA Progeria NDA Submission Complete by End of March 2020 Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif., March 13, 2020 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update2020-03-13T15:27:43+00:00
7 01, 2020

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

2020-01-07T14:48:46+00:00

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer Launch Preparation Underway for Lonafarnib in Progeria Market Development Activities Advancing for HDV Program PALO ALTO, Calif., January 7, 2020 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies [...]

Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer2020-01-07T14:48:46+00:00
6 01, 2020

Eiger Updates on 2019 Progress and 2020 Milestones Expected

2020-01-06T14:59:42+00:00

Eiger Updates on 2019 Progress and 2020 Milestones Expected Progeria Rolling NDA Planned for Completion in 1Q 2020 HDV Phase 3 D-LIVR Study Enrollment Planned to Complete in 2020 Commercial Focus on Progeria Launch Preparation and HDV Market Building Strong Balance Sheet with ~$95M in Cash and Investments to Begin 2020 PALO ALTO, Calif., [...]

Eiger Updates on 2019 Progress and 2020 Milestones Expected2020-01-06T14:59:42+00:00
7 11, 2019

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-07T21:42:42+00:00

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, [...]

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update2019-11-07T21:42:42+00:00
29 08, 2019

Eiger BioPharmaceuticals to Participate in September Conferences

2019-08-29T20:16:25+00:00

Eiger BioPharmaceuticals to Participate in September Conferences PALO ALTO, Calif. – August 29, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor conferences in September: Baird 2019 Global Healthcare Conference at the [...]

Eiger BioPharmaceuticals to Participate in September Conferences2019-08-29T20:16:25+00:00
17 06, 2019

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)

2019-06-17T20:57:19+00:00

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) Third Eiger Pipeline Program Granted Breakthrough Therapy Designation PALO ALTO, Calif., June 17, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food [...]

Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)2019-06-17T20:57:19+00:00